JP2019521990A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521990A5 JP2019521990A5 JP2018565845A JP2018565845A JP2019521990A5 JP 2019521990 A5 JP2019521990 A5 JP 2019521990A5 JP 2018565845 A JP2018565845 A JP 2018565845A JP 2018565845 A JP2018565845 A JP 2018565845A JP 2019521990 A5 JP2019521990 A5 JP 2019521990A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use according
- item
- subject
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662351234P | 2016-06-16 | 2016-06-16 | |
| US62/351,234 | 2016-06-16 | ||
| PCT/US2017/038003 WO2017218974A2 (en) | 2016-06-16 | 2017-06-16 | Treatment of amd using aav2 variant with aflibercept |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020155475A Division JP2020203941A (ja) | 2016-06-16 | 2020-09-16 | アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019521990A JP2019521990A (ja) | 2019-08-08 |
| JP2019521990A5 true JP2019521990A5 (enExample) | 2020-07-02 |
| JP6814822B2 JP6814822B2 (ja) | 2021-01-20 |
Family
ID=60663653
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565845A Active JP6814822B2 (ja) | 2016-06-16 | 2017-06-16 | アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 |
| JP2020155475A Withdrawn JP2020203941A (ja) | 2016-06-16 | 2020-09-16 | アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 |
| JP2022113865A Pending JP2022137244A (ja) | 2016-06-16 | 2022-07-15 | アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 |
| JP2024095160A Pending JP2024113193A (ja) | 2016-06-16 | 2024-06-12 | アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 |
| JP2025152535A Pending JP2025186377A (ja) | 2016-06-16 | 2025-09-12 | アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020155475A Withdrawn JP2020203941A (ja) | 2016-06-16 | 2020-09-16 | アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 |
| JP2022113865A Pending JP2022137244A (ja) | 2016-06-16 | 2022-07-15 | アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 |
| JP2024095160A Pending JP2024113193A (ja) | 2016-06-16 | 2024-06-12 | アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 |
| JP2025152535A Pending JP2025186377A (ja) | 2016-06-16 | 2025-09-12 | アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20190151409A1 (enExample) |
| EP (3) | EP4671369A3 (enExample) |
| JP (5) | JP6814822B2 (enExample) |
| KR (2) | KR102218265B1 (enExample) |
| CN (2) | CN117531025A (enExample) |
| AU (3) | AU2017286673B2 (enExample) |
| BR (1) | BR112018076124A2 (enExample) |
| CA (1) | CA3027737A1 (enExample) |
| CY (1) | CY1123697T1 (enExample) |
| DK (2) | DK3471780T3 (enExample) |
| ES (2) | ES3049818T3 (enExample) |
| FI (1) | FI3795181T3 (enExample) |
| HR (2) | HRP20251248T1 (enExample) |
| HU (1) | HUE051953T2 (enExample) |
| IL (3) | IL314568B2 (enExample) |
| LT (2) | LT3471780T (enExample) |
| MX (2) | MX391779B (enExample) |
| PL (1) | PL3795181T3 (enExample) |
| PT (2) | PT3795181T (enExample) |
| RS (2) | RS67328B1 (enExample) |
| SG (1) | SG11201811232XA (enExample) |
| SI (2) | SI3471780T1 (enExample) |
| SM (2) | SMT202100010T1 (enExample) |
| WO (1) | WO2017218974A2 (enExample) |
| ZA (1) | ZA201808538B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3800191B1 (en) | 2014-03-17 | 2025-08-20 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression in cone cells |
| JP7095994B2 (ja) | 2015-03-02 | 2022-07-05 | アドヴェラム バイオテクノロジーズ， インコーポレイテッド | ポリヌクレオチドを網膜錐体に硝子体内送達するための組成物及び方法 |
| SI3471780T1 (sl) * | 2016-06-16 | 2021-03-31 | Adverum Biotechnologies, Inc. | Zdravljenje SDM-ja z uporabo različice AAV2 z afliberceptom |
| CA3040179A1 (en) | 2016-10-19 | 2018-04-26 | Adverum Biotechnologies, Inc. | Modified aav capsids and uses thereof |
| EP4653536A3 (en) | 2017-03-17 | 2026-02-25 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression |
| CN107537026A (zh) * | 2017-08-31 | 2018-01-05 | 中山大学中山眼科中心 | Vegf‑b的应用 |
| CN107661492A (zh) * | 2017-08-31 | 2018-02-06 | 中山大学中山眼科中心 | Vegf‑b的新用途 |
| AU2018350990A1 (en) * | 2017-10-18 | 2020-05-21 | Regenxbio Inc. | Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap |
| ES2946747T3 (es) * | 2017-11-27 | 2023-07-25 | 4D Molecular Therapeutics Inc | Variantes de cápsides de virus adenoasociado y su utilización para inhibir la angiogénesis |
| BR112020012336A2 (pt) | 2017-12-19 | 2021-03-30 | Akouos, Inc. | Administração de anticorpos terapêuticos mediada por aav para o ouvido interno |
| EP3773677B1 (en) * | 2018-04-12 | 2025-04-02 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Anti-aging compositions and methods of use |
| JP7235770B2 (ja) | 2018-05-10 | 2023-03-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤 |
| EP3934698A1 (en) * | 2019-03-04 | 2022-01-12 | Adverum Biotechnologies, Inc. | Sequential intravitreal administration of aav gene therapy to contralateral eyes |
| TW202106708A (zh) * | 2019-04-24 | 2021-02-16 | 美商銳進科斯生物股份有限公司 | 全人類轉譯後修飾之抗體治療劑 |
| MA54325A (fr) | 2019-06-05 | 2022-05-11 | Regeneron Pharma | Dispositifs et procédés pour l'administration précise de doses |
| CN114390928A (zh) * | 2019-09-11 | 2022-04-22 | 阿德夫拉姆生物技术股份有限公司 | 使用编码阿柏西普的aav2变体治疗眼新血管疾病的方法 |
| WO2021050649A1 (en) * | 2019-09-11 | 2021-03-18 | Adverum Biotechnologies, Inc. | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
| TWI819268B (zh) | 2020-01-16 | 2023-10-21 | 詹姆斯 Ｗ 希爾 | 藉由基因轉導改變眼睛顏色 |
| FR3111913A1 (fr) * | 2020-06-30 | 2021-12-31 | Eyevensys | Construction d’adn pour le traitement de pathologies oculaires |
| AU2021313839A1 (en) * | 2020-07-21 | 2023-03-23 | FTGEN Corp | Composition and method for treating eye diseases |
| CN113952473A (zh) * | 2020-07-21 | 2022-01-21 | 英斯培瑞有限公司 | 用于治疗眼部疾病的组合物和方法 |
| CN113952474A (zh) * | 2020-07-21 | 2022-01-21 | 英斯培瑞有限公司 | 用于治疗眼部疾病的组合物和方法 |
| CN113817775B (zh) * | 2020-08-25 | 2023-02-17 | 南京吉迈生物技术有限公司 | 修饰的阿柏西普、组合物、方法及其在基因治疗中的应用 |
| US20230340529A1 (en) * | 2020-09-03 | 2023-10-26 | University Of Massachusetts | Adeno-associated virus for delivery of kh902 (conbercept) and uses thereof |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| JP2021049374A (ja) * | 2020-12-09 | 2021-04-01 | 株式会社三洋物産 | 遊技機 |
| BR112023019056A2 (pt) * | 2021-04-27 | 2024-01-16 | Adverum Biotechnologies Inc | Métodos para tratar doenças oculares usando variantes de aav2 que codificam aflibercepte |
| CN118660913A (zh) | 2022-02-21 | 2024-09-17 | 上海瑞宏迪医药有限公司 | Vegf结合分子及其医药用途 |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| TW202508610A (zh) | 2023-08-23 | 2025-03-01 | 大陸商上海瑞宏迪醫藥有限公司 | 醫藥組成物及其用途 |
| WO2025072688A2 (en) * | 2023-09-27 | 2025-04-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Adeno-associated virus vectors for nucleic acid delivery to retinal cells, for nucleic acid delivery across retinal regions, or for nucleic acid delivery to retinal ganglion cells and/or retinal pigment epithelium cells |
| WO2025073297A1 (zh) * | 2023-10-06 | 2025-04-10 | 甘李药业股份有限公司 | 表达抗vegf融合蛋白的aav病毒载体及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107012171B (zh) * | 2011-04-22 | 2021-07-13 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
| PL2846836T3 (pl) * | 2012-05-07 | 2020-01-31 | Allergan, Inc. | Sposób leczenia amd u pacjentów opornych na terapię anty- vegf |
| TWI775096B (zh) * | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| WO2013188316A1 (en) * | 2012-06-11 | 2013-12-19 | Avalanche Biotechnologies, Inc. | Optical regulation of gene expression in the retina |
| KR102948178B1 (ko) * | 2013-07-12 | 2026-04-10 | 아스텔라스 유에스 엘엘씨 | 안과적 질환을 치료하거나 예방하기 위한 방법 |
| MX377714B (es) * | 2013-10-18 | 2025-03-11 | Regeneron Pharma | Composiciones que comprenden una combinación de un antagonista de vegf y un anticuerpo anti-ctla-a. |
| JP7095994B2 (ja) * | 2015-03-02 | 2022-07-05 | アドヴェラム バイオテクノロジーズ， インコーポレイテッド | ポリヌクレオチドを網膜錐体に硝子体内送達するための組成物及び方法 |
| SI3471780T1 (sl) * | 2016-06-16 | 2021-03-31 | Adverum Biotechnologies, Inc. | Zdravljenje SDM-ja z uporabo različice AAV2 z afliberceptom |
-
2017
- 2017-06-16 SI SI201730553T patent/SI3471780T1/sl unknown
- 2017-06-16 JP JP2018565845A patent/JP6814822B2/ja active Active
- 2017-06-16 EP EP25187377.4A patent/EP4671369A3/en active Pending
- 2017-06-16 HU HUE17814223A patent/HUE051953T2/hu unknown
- 2017-06-16 PT PT201966579T patent/PT3795181T/pt unknown
- 2017-06-16 PT PT178142238T patent/PT3471780T/pt unknown
- 2017-06-16 SG SG11201811232XA patent/SG11201811232XA/en unknown
- 2017-06-16 WO PCT/US2017/038003 patent/WO2017218974A2/en not_active Ceased
- 2017-06-16 HR HRP20251248TT patent/HRP20251248T1/hr unknown
- 2017-06-16 CN CN202311530329.4A patent/CN117531025A/zh active Pending
- 2017-06-16 DK DK17814223.8T patent/DK3471780T3/da active
- 2017-06-16 SI SI201731629T patent/SI3795181T1/sl unknown
- 2017-06-16 KR KR1020197001023A patent/KR102218265B1/ko active Active
- 2017-06-16 ES ES20196657T patent/ES3049818T3/es active Active
- 2017-06-16 AU AU2017286673A patent/AU2017286673B2/en active Active
- 2017-06-16 PL PL20196657.9T patent/PL3795181T3/pl unknown
- 2017-06-16 HR HRP20201842TT patent/HRP20201842T1/hr unknown
- 2017-06-16 IL IL314568A patent/IL314568B2/en unknown
- 2017-06-16 CA CA3027737A patent/CA3027737A1/en active Pending
- 2017-06-16 RS RS20251055A patent/RS67328B1/sr unknown
- 2017-06-16 ES ES17814223T patent/ES2840059T3/es active Active
- 2017-06-16 DK DK20196657.9T patent/DK3795181T3/da active
- 2017-06-16 EP EP17814223.8A patent/EP3471780B1/en active Active
- 2017-06-16 KR KR1020217004488A patent/KR20210021113A/ko not_active Ceased
- 2017-06-16 LT LTEP17814223.8T patent/LT3471780T/lt unknown
- 2017-06-16 RS RS20201517A patent/RS61311B1/sr unknown
- 2017-06-16 MX MX2018015512A patent/MX391779B/es unknown
- 2017-06-16 IL IL279919A patent/IL279919B2/en unknown
- 2017-06-16 CN CN201780050283.2A patent/CN109641065A/zh active Pending
- 2017-06-16 SM SM20210010T patent/SMT202100010T1/it unknown
- 2017-06-16 LT LTEP20196657.9T patent/LT3795181T/lt unknown
- 2017-06-16 FI FIEP20196657.9T patent/FI3795181T3/fi active
- 2017-06-16 EP EP20196657.9A patent/EP3795181B1/en active Active
- 2017-06-16 SM SM20250400T patent/SMT202500400T1/it unknown
- 2017-06-16 BR BR112018076124A patent/BR112018076124A2/pt active Search and Examination
-
2018
- 2018-12-12 US US16/218,353 patent/US20190151409A1/en not_active Abandoned
- 2018-12-13 MX MX2022004786A patent/MX2022004786A/es unknown
- 2018-12-13 IL IL263686A patent/IL263686B/en active IP Right Grant
- 2018-12-18 ZA ZA2018/08538A patent/ZA201808538B/en unknown
-
2020
- 2020-09-16 JP JP2020155475A patent/JP2020203941A/ja not_active Withdrawn
- 2020-11-30 CY CY20201101133T patent/CY1123697T1/el unknown
-
2021
- 2021-09-01 AU AU2021225178A patent/AU2021225178B2/en active Active
- 2021-09-20 US US17/479,968 patent/US20220265740A1/en active Pending
-
2022
- 2022-07-15 JP JP2022113865A patent/JP2022137244A/ja active Pending
-
2024
- 2024-06-12 JP JP2024095160A patent/JP2024113193A/ja active Pending
-
2025
- 2025-04-28 AU AU2025202930A patent/AU2025202930A1/en active Pending
- 2025-09-12 JP JP2025152535A patent/JP2025186377A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019521989A5 (enExample) | ||
| HRP20201842T1 (hr) | Liječenje amd korištenjem aav2 varijante s afliberceptom | |
| JP2022183183A5 (enExample) | ||
| FI3717636T3 (fi) | Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä | |
| JP2021503914A5 (enExample) | ||
| JP2018520646A5 (enExample) | ||
| Barnett et al. | Complications of retinopathy of prematurity treatment | |
| CN115554418B (zh) | 一种重组腺相关病毒载体的药物组合物及其用途 | |
| CN108368165A (zh) | 用于治疗颅内出血相关症状的方法和组合物 | |
| JP2018517773A (ja) | ＩｇＧＦｃドメインを有する融合タンパク質の安定な液状製剤 | |
| JP2018527941A5 (enExample) | ||
| JP2019509750A (ja) | 生弱毒化アルファウイルス構築物及び方法、ならびにそれらの使用 | |
| US11000577B2 (en) | Compositions and methods for treating neonatal biliary atresia | |
| JP2020510648A5 (enExample) | ||
| JP2018509154A5 (enExample) | ||
| JP2023515916A (ja) | 神経損傷及び関連障害を治療するための方法 | |
| CN117180455A (zh) | 腺相关病毒药物组合物及其用途 | |
| Aziz et al. | Review of gene therapy clinical trials for retinal diseases | |
| TWI788779B (zh) | 一種治療病毒性肺炎的方法和藥物 | |
| US20180000892A1 (en) | Methods and pharmaceutical compositions for the treatment of ischemic conditions | |
| JP2023525257A (ja) | 脊髄性筋萎縮症を治療する方法及び薬剤 | |
| CN119909180A (zh) | 一种治疗肌萎缩侧索硬化的方法和药物 | |
| JP7850132B2 (ja) | ＳＡＲＳ－ＣｏＶ－２感染患者におけるアウトカムを改善するための吸入インターフェロン－ベータ | |
| CN118831152A (zh) | 导管素抗菌肽在缺血性脑卒中药物中的应用 | |
| Ratra | Commentary: Switching of anti-vascular endothelial growth factor agents in refractory diabetic macular edema |